<DOC>
	<DOCNO>NCT00936208</DOCNO>
	<brief_summary>PRO-POWER observational cohort study period 24 week . All recruit patient essential hypertension . In addition , patient least one contribute risk factor cardiovascular event . The study aim evaluate safety , efficacy protection Micardis 80mg/Micardis plus 80/12.5mg cardiovascular risk patient essential hypertension</brief_summary>
	<brief_title>PRO-POWER : Hypertension With Risk Factors Duration 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Inclusion criterion : Male female Aged 20 80 year old . adult essential hypertension either newly diagnose untreated , previously treat uncontrolled Sitting blood pressure : systolic BP &gt; 140 mmHg &lt; 180 mmHg , and/or diastolic BP &gt; 90 mmHg &lt; 110 mmHg ) At least one cardiovascular know risk factor hypertension : diabetes/hyperglycaemia , cholesterol /dyslipidemia , previous cardiovascular event , target organ damage , family history hypertension cardiovascular disease , old age define &gt; 55 year ( Males ) , &gt; 65 year ( Females ) , smoke , overweight obese patient combination risk factor Patients assessed benefit intake angiotensin II receptor blocker ( ARB ) monotherapy addon medication Exclusion criterion : Patients contraindication Telmisartan use ( per Micardis® Tablets package insert ) . Known hypersensitivity active ingredient excipients Micardis® . Any clinical condition , opinion attend physician , would allow safe administration study medication . Patients participate clinical trial . Patients already Micardis® alone combination Pregnant female , female breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>